Elyxium Wealth LLC Acquires New Stake in CME Group Inc. (NASDAQ:CME)

Elyxium Wealth LLC acquired a new stake in CME Group Inc. (NASDAQ:CME - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 1,364 shares of the financial services provider's stock, valued at approximately $362,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in CME Group in the fourth quarter valued at $1,107,389,000. Price T Rowe Associates Inc. MD raised its stake in shares of CME Group by 89.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,280,785 shares of the financial services provider's stock worth $1,923,047,000 after buying an additional 3,921,278 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of CME Group by 32,941.0% during the 1st quarter. GAMMA Investing LLC now owns 1,858,887 shares of the financial services provider's stock worth $493,144,000 after buying an additional 1,853,261 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of CME Group by 38.7% during the 4th quarter. Franklin Resources Inc. now owns 3,366,786 shares of the financial services provider's stock worth $781,869,000 after buying an additional 939,679 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in shares of CME Group by 4,216.2% during the 4th quarter. Bessemer Group Inc. now owns 922,805 shares of the financial services provider's stock worth $214,301,000 after buying an additional 901,425 shares during the last quarter. 87.75% of the stock is currently owned by hedge funds and other institutional investors.

CME Group Stock Performance

Shares of CME opened at $274.70 on Friday. The business's 50 day moving average is $275.89 and its two-hundred day moving average is $260.85. CME Group Inc. has a 52-week low of $193.25 and a 52-week high of $290.79. The firm has a market cap of $98.99 billion, a price-to-earnings ratio of 27.64, a PEG ratio of 4.81 and a beta of 0.44. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.13.

CME Group (NASDAQ:CME - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.61 by $0.19. The company had revenue of $1.64 billion for the quarter, compared to analyst estimates of $1.56 billion. CME Group had a return on equity of 14.03% and a net margin of 57.71%. CME Group's quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.50 EPS. Analysts forecast that CME Group Inc. will post 10.49 EPS for the current fiscal year.

CME Group Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, June 25th. Investors of record on Monday, June 9th were given a dividend of $1.25 per share. This represents a $5.00 annualized dividend and a dividend yield of 1.82%. The ex-dividend date was Monday, June 9th. CME Group's dividend payout ratio is currently 50.30%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on CME shares. Erste Group Bank cut CME Group from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 24th. Wall Street Zen cut CME Group from a "hold" rating to a "sell" rating in a research report on Sunday, July 13th. UBS Group lifted their price objective on CME Group from $290.00 to $305.00 and gave the stock a "buy" rating in a research report on Friday, April 25th. Barclays lifted their price objective on CME Group from $283.00 to $299.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 10th. Finally, Citigroup lifted their price objective on CME Group from $265.00 to $275.00 and gave the stock a "neutral" rating in a research report on Thursday, July 3rd. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $261.80.

Insider Buying and Selling at CME Group

In related news, Director Charles P. Carey sold 500 shares of the company's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $265.35, for a total transaction of $132,675.00. Following the completion of the transaction, the director directly owned 4,900 shares in the company, valued at $1,300,215. This represents a 9.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Phyllis M. Lockett sold 1,060 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $277.88, for a total value of $294,552.80. Following the completion of the transaction, the director directly owned 3,108 shares of the company's stock, valued at approximately $863,651.04. The trade was a 25.43% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,400 shares of company stock worth $3,680,610. 0.30% of the stock is owned by insiders.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.